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ABSTRACT 
Albuminuria predicts cardiovascular disease (CVD) 
events but it is likely to vary over time in a non- 
linear fashion. The aim of this study was to es-
timate the potentially differing predictive effect 
of albuminuria on the risk of CVD or related 
death over time. Data were from a cohort study 
of 3505 predominately indigenous adults from 
remote communities in Queensland, Australia, 
1999-2006. Cox Proportional Hazards model 
analysis of the predictive effects of urinary al-
bumin creatinine ratio on the risk of CVD or 
CVD-related death was undertaken for incident 
and prevalent CVD. Analyses sequentially re-
moved those who had a cardiovascular event or 
related death for the first year through to six 
years. The baseline prevalence of microalbu-
minuria was 21.2% and for macroalbuminuria 
6.7%. The incidence of CVD was 92 in 13,812 
person-years. Microalbuminuria predicted inci-
dent CVD with a Hazard Ratio (HR) of 3.0 (95% CI 
1.83 - 4.96) and for macroalbuminuria HR 10.8 
(95% CI 6.58 - 17.68) and for those with pre-ex-
isting CVD, HR 2.6 (95% CI 1.65 - 3.97) and HR 
9.7 (95% CI 6.38 - 14.82) respectively. People 
with macroalbuminuria who survived the first 
three years had a crude HR of an incident car-
diovascular event or death of 13.0 (95% CI 6.45 - 
26.39) to a peak of 32.3 (95% CI 8.55 - 121.77) for 
those who survived the first five years. The 
hazard appeared to drop in the 6th year although 
this is based on small numbers. The first three 
years after finding macroalbuminuria provide a 
potential window opportunity to actively manage 
the risk of incident CVD before the risk elevates. 
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1. INTRODUCTION 
Albuminuria is a well established independent risk 
factor for cardiovascular disease events and associated 
mortality. This has been reported in both high risk and 
general population cohorts [1-3]. The mechanism for this 
association is not clear, however a number of hypotheses 
have been proposed. The association may be accounted 
for by albuminuria as a marker of reduced renal function, 
which is associated with increased cardiovascular disease 
(CVD) risk [4]. Additionally, it may be that widespread 
endothelial damage leads both to albuminuria and CVD 
through enhanced atherogenesis [4]. It is also possible 
that a common factor, such as hypertension, leads to both 
albuminuria and CVD [5]. 
The range of studies reporting this association assume 
constant risk (or hazard) over time. This is unlikely to be 
true biologically as a high level of macroalbuminuria is 
more likely in an advanced stage of disease such that the 
risk of a cardiovascular event is greater in the short term 
than those with lesser levels of macroalbuminuria, all 
other factors equal. As such, using a model such as the 
Cox model which assumes constant hazard over time 
may not adequately estimate the risk of albuminuria for 
cardiovascular disease. In this scenario, the hazard over 
the length of the study period may overestimate the risk 
in the short term and underestimate it in the long term. 
This has implications on the importance clinicians place 
on management of albuminuria in the prevention of both 
advanced renal and cardiovascular disease in the short 
term to reduce greater risk in the long term. 
To examine this further, we used data from the Well 
Person’s Health Check (WPHC), a cohort study in North 
Queensland conducted in 26 remote Aboriginal and Tor-
res Strait Islander communities [6]. This general popula-
tion cohort has previously documented high levels of 
albuminuria and CVD [7] and so provides an opportunity 
to examine the effect of changing risk of albuminuria on 
cardiovascular disease over time. 
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2. MATERIALS AND METHODS 
2.1. Study Population 
Baseline data were collected from 3505 people in 26 
rural Indigenous communities in Far North Queensland, 
who participated in the “Well Person’s Health Check” 
between 1999 and 2000 (methods for this cross-sectional 
study have been reported in detail elsewhere [6]). Based 
on the local census data, the study achieved a participa-
tion rate of 44.5% with greater participation noted in 
smaller communities. 
2.2. Albumin Creatinine Ratio 
All participants were asked to provide urine from the 
first morning void or to delay providing the sample for at 
least two hours from the most recent void. First catch 
urine samples were self-collected in a sterile 50 ml con-
tainer. All urine specimens were refrigerated at four to 
eight degrees centigrade immediately following collec-
tion. A five to ten millilitre sample from the collection 
jar was transferred into a ten-millilitre tube. Dipstick 
urinalysis (Combur-test, Roche) was performed on the 
remaining sample and the results for protein recorded. 
For the first 15 months of the recruitment period (of a 
total recruitment period of 34 months) albumin creatinine 
ratio (ACR) testing was performed when the participants’ 
urine contained protein (detected on urinalysis) or they 
were known to have diabetes, hypertension or had a body 
mass index over 30 kg/m2. For the subsequent 19 months 
of recruitment ACR testing was performed routinely on 
all urine specimens [6]. Microalbuminuria was defined 
as a urinary ACR of 3.4 mg/mmol to 33.9 mg/mmol and 
macroalbuminuria of 34 mg/mmol or greater.  
2.3. CVD Event or Related Death 
A cardiovascular event or related death was deter-
mined from unit-level record linkage of the cohort mem- 
bers to hospitalisation records and deaths up to a census 
date of 1 January 2006. Hospitalisation and death records 
for consenting WPHC participants were identified by a 
manual search (conducted by a registered nurse with 
experience working in the region) of the Queensland 
Health hospital records systems. As there is no unique 
patient identifier in Queensland, a mapping table, which 
linked WPHC reference number, hospital facility code 
and local unit record number, was developed. This table 
was subsequently applied to the Queensland Hospital 
Admitted Patient Data Collection, and hospitalisation 
relevant to the match unit record, facility code tuples 
were extracted. Matching of death records was per-
formed manually at the Queensland Registry of Births, 
Deaths and Marriages.  
Hospitalisations were considered to be CVD related if 
they contained an International Classification of Diseases, 
ninth revision, clinical modification (ICD-9-CM) code 
commencing with 410, 411, 413 or 414, or an ICD-9-CM 
procedure code between 3600 and 3699, inclusive. For 
hospitalisations coded to the International Classification 
of Diseases, 10th revision, the diagnosis code range I20 - 
I25, and procedure code blocks 669 - 679, inclusive, 
were used. 
Both incident CVD and a separate analysis on the 
whole sample that also included those with pre-existing 
CVD were undertaken. Prior cardiovascular disease was 
determined from participant report of a history of car-
diovascular disease or from a case note review at study 
entry or hospitalisation (using the same International 
Classification of Diseases codes as above) recorded prior 
to study entry. 
2.4. Baseline Data 
Current smoking was defined as regular smoking of at 
least one cigarette a day. Blood pressure was the average 
of three measurements taken while seated over a ten 
minute period. Height and weight were measured, with 
weight recorded to the nearest 0.1 kg and height recorded 
to the nearest centimetre. Body mass index was calcu-
lated as weight (kg) divided by the height squared (m2) 
and categorised by using WHO definition of overweight 
and obesity [8]. 
Blood for total cholesterol was collected by trained 
health staff. Blood was collected in an eight point millili-
tre clotted (SST) vacuum tube which was spun for 10 
minutes in a portable centrifuge within one hour of col-
lection and measured by photometric enzyme end point 
assay, using the Cobas Integra 700/400 (Roche Diagnos-
tics, New York, USA). 
Prior history of diabetes at baseline was determined 
from a report at interview of diabetes or case note review 
or a fasting blood glucose level of ≥7 mmol/L, 2-hour 
glucose tolerance test result of ≥11.1 mmol/L at study 
entry, or documented hospitalisation for diabetes prior to 
study entry (through the linkage process described above 
for ICD-09 codes E11-E14).  
2.5. Study Sample 
Those who did not have an ACR measured (n = 643) 
and missing data on variables blood pressure or smoking 
(a further n = 413), date of the first screen (n = 1) or for 
cause of death (n = 3) lead to a sample for analysis of 
2445. Exclusion of those with pre-existing CVD brought 
the sample to 2349. As noted above, the majority of the 
ACR data were missing due to the selection criteria of 
the study and not at random. 
2.6. Analysis 
A descriptive analysis was undertaken comparing 
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those participants who did and did not have an ACR 
taken or had missing data was undertaken, using chi 
square test or a student’s t-test. 
All CVD related deaths or events (CVD) were pooled 
for subsequent analyses. Time in the study was calcu-
lated from date of first screen to CVD or death from any 
cause or the census date (whichever occurred first). Car-
diovascular event or death rates per 1000 person-years 
were analysed using the Kaplan-Meier method by ACR 
category. 
The effect of ACR level at baseline on CVD was ana-
lysed using a Cox Proportional Hazards model, estimat-
ing a Hazard Ratio (HR). This analysis was conducted on 
the entire study sample with a total of up to seven years 
of follow up (n = 2445), assuming proportional hazards 
over time. In order to assess the potential effect of dif-
fering hazard over time, the analysis was repeated by 
excluding all those events or deaths that occurred in the 
first year subsequent to study entry and then again ex-
cluding the events or deaths that occurred in the first two 
years subsequent to study entry, and so on until six years 
from study entry. In this way these models assess the 
subsequent risk of a CVD event or related death for peo-
ple who survived from one to six years following study 
entry.  
Crude Hazard Ratios were calculated using Cox mod-
els. The independent contribution of albuminuria as a 
marker of cardiovascular disease risk was estimated us-
ing multivariate analysis. For each of the time periods, 
the analysis was conducted first adjusted for sex and age 
only (model 2, there was minimal difference in estimates 
stratified by gender and so to maximize precision the 
analysis controlled for gender rather than stratifying by 
gender). The second model further adjusted for a history 
of prior CVD and the third model also adjusted for 
smoking status, systolic blood pressure (adding diastolic 
blood pressure to the model did not appreciably alter 
results and so was omitted, data not shown), diabetes, 
body mass index and total cholesterol level, factors that 
have been previously found to have an association both 
with CVD and ACR [4,9,10]. All analyses were con-
ducted using Stata statistical software v 10.0 [11]. The 
study was approved by the Cairns and Hinterland Health 
Service District Ethics Committee, with support from the 
relevant peak Indigenous health councils. All participants 
gave informed consent. 
3. RESULTS 
The study cohort had a 21.2% baseline prevalence of 
microalbuminuria and 6.7% of macroalbuminuria, with 
no difference between men and women (p = 0.3). Table 
1 shows the baseline characteristics of the study popula-
tion, comparing the study sample with those who par-
ticipated in the baseline survey but either did not have an 
ACR taken (as they were deemed to be ‘low risk’) or had 
missing data. The study sample, was more likely to be 
female, had higher blood pressure, higher BMI, lower 
total cholesterol, higher prevalence of diabetes and was 
older, but there was no difference in the prevalence of 
smoking. 
The rate of incident CVD events or death per 1000 
person-years by ACR category and length of time since 
study entry is presented in Table 2. The overall inci-
dence of cardiovascular event or death was 92 in 13,812 
person-years. The rate increased across ACR category 
from normal (3.3, 95% CI 2.3 - 4.6) to microalbuminuria 
(9.8, 95% CI 6.8 - 14.1) and then macroalbuminuria 
(35.5, 95% CI 24.8 - 50.8). 
Kaplan-Meier survival estimates are presented in the 
Figure 1. There was decreasing survival with increases 
in level of albuminuria.  
The overall risk of an incident cardiovascular event or 
death was 1.3 (95% CI 0.78 - 2.31) for microalbuminuria  
 
Table 1. Baseline characteristics of the study sample (analysis cohort) and those who had missing data and were excluded from the 
analysis, Well Person’s Health Check, 1999-2006, n = 3377. 
Variable (mean unless otherwise indicated) Study sample n = 2445 (95% CI†) 
Missing ACR and other covariates n = 932
(95% CI) 
Age* 36.9 (36.2 - 37.5) 34.2 (33.3 - 35.1) 
Female* (%)  53.2 (51.2 - 55.1) 47.8 (44.7 - 50.7) 
Smoker (%) 51.8 (49.8 - 53.8) 52.2 (49.2 - 55.3) 
Systolic blood pressure* 129.5 (128.7 - 130.2) 124.6 (123.5 - 125.6) 
Body Mass Index* 27.7 (27.4 - 28.0) 26.1 (25.7 - 26.5) 
Total cholesterol* 4.8 (4.78 - 4.87) 5.0 (4.9 - 5.1) 
Diabetes*(%) 14.3 (12.9 - 15.7) 8.9 (7.2 - 10.6) 
*p value ≤ 0.05; †CI confidence interval. 
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Table 2. Incident cardiovascular events or death rates per 1000 person years, by category of albuminuria and years since study entry, 
Well Person’s Health Check, 1999-2006, n = 2349. 
 Normal Microalbuminuria Macroalbuminuria 
Time 
(Years) Person-years Events Rate (95% CI
†) Person-years Events Rate (95% CI†) Person-years Events Rate (95% CI†) 
0 - 1 1687.4 6 3.6 (1.6 - 7.9) 493.9 5 10.1 (4.2 - 24.3) 150.8 10 66.3 (35.7 - 123.2)
1 - 2 1675.1 4 2.4 (0.9 - 6.4) 487.9 7 14.3 (6.8 - 30.1) 142.6 2 14.0 (3.5 - 56.1)
2 - 3 1664.6 8 4.8 (2.4 - 9.6) 476.3 5 10.5 (4.4 - 25.2) 138.2 2 14.5 (3.6 - 57.9)
3 - 4 41654.6 8 4.8 (2.4 - 9.7) 468.5 4 8.5 (3.2 - 22.7) 136.6 4 29.3 (11.0 - 78.0)
4 - 5 1644.4 4 2.4 (0.9 - 6.5) 462.0 5 10.8 (4.5 - 26.0) 131.5 4 30.4 (11.4 - 81.0)
5 - 6 1123.8 2 1.8 (0.4 - 7.1) 355.4 2 5.6 (1.4 - 22.5) 90.8 7 77.1 (36.8 - 161.7)
6 - 7 488.0 1 2.0 (0.3 - 14.5) 186.0 0 0 46.4 1 21.5 (3.0 - 153.0)
7+ 73.2 0 - 27.7 1 36.1 (5.1 - 256.1) 7.0 0 0 
Total 10011.1 33 3.3 (2.3 - 4.6) 2957.8 29 9.8 (6.8 - 14.1) 843.9 30 35.5 (24.8 - 50.8)
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Figure 1. Kaplan-Meier survival estimate by albuminuria 
category for incident cardiovascular disease, Well Person’s 
Health Check, 1999-2006, n = 2349. 
 
and 4.4 (95% CI 2.52 - 7.83) for macroalbuminuria 
compared with normal levels of albuminuria, when ad-
justing for age, gender, smoking, systolic blood pressure, 
total cholesterol and diabetes (Table 3, model 3). The 
equivalent risk estimates for the sample that included 
those with pre-existing CVD was similar, with a HR of 
1.1 (95% CI 0.70 - 1.80) for microalbuminuria and 3.8 
(95% CI 2.37 - 6.24) for macroalbuminuria. The risk was 
lowest for people with macroalbuminuria in the first 
three years. For example, those people with macroalbu-
minuria that survived the first three years had a crude HR 
of an incident cardiovascular event or death of 13.0 (95% 
CI 6.45 - 26.39) to a peak of 32.3 (95% CI 8.55 - 121.77) 
for those who survived the first five years (multivariate 
adjustment not undertaken due to small event numbers). 
The hazard dropped in the 6th year although this estimate 
is based on small numbers.  
4. DISCUSSION 
Macroalbuminuria increased the risk of an incident 
cardiovascular event or death, with increasing magnitude 
over time, ranging from a HR of 9.0 for those who sur-
vived the first year to HR 32.3 for those who survived 
the first five years. These estimates were attenuated by 
age, gender and the co-variates added to the model, but a 
strong independent association with cardiovascular dis-
ease remained. The estimates that included those with 
pre-existing CVD were similar in magnitude to those for 
incident CVD, suggesting that albuminuria may be a 
relevant clinical indicator in both primary health care and 
specialist medical settings. Microalbuminuria also con-
sistently elevated the risk of a cardiovascular event or 
death compared with normal (less so than macroalbu-
minuria), but did not appear to follow the same time 
varying pattern as macroalbuminuria. These findings 
suggest that the risks associated with macroalbuminuria 
are less in the first three years than the overall hazard 
would suggest and so suggest that a window of opportu-
nity exists to reduce incident cardiovascular disease and 
a subsequent CVD event or related death for those with 
pre-existing CVD before the risk increases up to three 
fold over the next three years. 
The hazard ratio for those who survived the first six 
years was a third of that for the previous five year esti-
mate. This difference may reflect small numbers of 
events in the seventh year and so be an unstable and 
non-valid estimate. However, if this is a true finding it 
suggests that macroalbuminuria is a strong predictor of 
incident cardiovascular disease in the short term (within 
the first six years) and less so in the long term. This 
finding is consistent with a study conducted in 1993  
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Table 3. Level of albuminuria on the risk of cardiovascular event or death, Well Person’s Health Check, 1999-2006. 
  Incident cardiovascular disease, n = 2349 Including pre-existing cardiovascular disease, n = 2445
  
Model 1: Crude  
Hazard Ratio,  
(95% CI‡) 
Model 2†:  
Hazard Ratio, 
(95% CI) 
Model 3: Hazard 
Ratio, (95% CI)
Model 1: Crude 
Hazard Ratio, 
(95% CI) 
Model 2: Hazard 
Ratio, (95% CI) 
Model 3:  
Hazard Ratio, 
(95% CI) 
All Years Micro§ 3.0 (1.83 - 4.96) 1.6 (0.97 - 2.73) 1.3 (0.78 - 2.31) 2.6 (1.65 - 3.97) 1.4 (0.86 - 2.13) 1.1 (0.70 - 1.80)
 Macro§ 10.8 (6.58 - 17.68) 6.1 (3.66 - 10.15) 4.4 (2.52 - 7.83) 9.7 (6.38 - 14.82) 5.3 (3.45 - 8.22) 3.8 (2.37 - 6.24)
1 Year¶ Micro 3.0 (1.76 - 5.28) 1.6 (0.9102.87) 1.3 (0.71 - 2.33) 2.7 (1.66 - 4.42) 1.4 (0.85 - 2.32) 1.13 (0.67 - 1.92)
 Macro 9.0 (5.03 - 15.98) 5.1 (2.79 - 9.16) 3.5 (1.82 - 6.75) 8.1 (4.90 - 13.43) 4.5 (2.66 - 7.48) 3.1 (1.72 - 5.41)
2 Years Micro 2.7 (1.45 - 4.97) 1.4 (0.74 - 2.67) 1.2 (0.60 - 2.29) 2.5 (1.43 - 4.44) 1.3 (0.72 - 2.30) 1.1 (0.59 - 1.98)
 Macro 9.5 (5.14 - 17.66) 5.4 (2.84 - 10.09) 4.1 (2.05 - 8.29) 9.7 (5.64 - 16.78) 5.3 (3.05 - 9.32) 4.0 (2.14 - 7.39)
3 Years Micro 2.7 (1.27 - 5.82) 1.6 (0.71 - 3.41) 1.4 (0.63 - 3.20) 2.5 (1.23 - 4.91) 1.4 (0.68 - 2.82) 1.2 (0.58 -2.55)
 Macro 13.0 (6.45 - 26.39) 7.9 (3.84 - 16.36) 6.9 (3.07 - 15.43) 10.2 (5.32 - 19.72) 6.2 (3.17 - 12.08) 4.9 (2.33 - 10.51)
4 Years Micro 3.8 (1.38 - 10.52) 2.2 (0.77 - 6.30) 2.2 (0.75 - 6.46) 3.0 (1.20 - 7.27) 1.3 (0.57 - 3.17) 1.6 (0.62 - 4.17)
 Macro 21.1 (8.31 - 53.65) 13.1 (5.02 - 34.01) 11.8 (4.14 - 33.59) 14.9 (6.55 - 34.10) 7.2 (3.38 - 15.23) 7.7 (3.01 - 19.86)
5 Years Micro 3.1 (0.63 - 15.56) 1.7 (0.34 - 8.95) - 1.9 (0.44 - 7.80) 1.0 (0.23 - 4.32) - 
 Macro 32.3 (8.55 - 121.77) 19.2 (4.94 - 74.41) - 20.3 (6.81 - 60.76) 11.8 (3.88 - 36.23) - 
6 Years Micro 2.6 (0.16 - 42.00) - - 1.3 (0.12 - 14.40) - - 
 Macro 10.1 (0.63 - 161.1) - - 4.80 (0.43 - 52.91) - - 
†Model 2: adjusted for age and gender; Model 3: also adjusted for baseline smoking, systolic blood pressure, total cholesterol and diabetes. ‡CI confidence 
interval. §Micro—microalbuminuria, Macro—macroalbuminuria. ¶Each year denotes the number of events excluded—e.g. 1 year analyses all data excluding 
those who had a cardiovascular event or death in the previous 1 year, 2 year analyses all data excluding those who had a cardiovascular event or death in the 
first 2 years, etc. 
 
where after 5 years the predictive effect of albuminuria 
on the risk of CVD had reduced to no effect [12]. This 
suggests the possibility of different trajectories of risk for 
different potential causal pathways between macroalbu-
minuria and cardiovascular disease, with one or more 
trajectories leading to a short term high increased risk of 
death and a possible other whereby macroalbuminuria is 
less predictive of cardiovascular disease from the start. 
Another possible explanation is a healthy survivor effect, 
where those who survive or do not develop cardiovascu-
lar disease by five years being healthier (in ways for 
which we were unable to adjust) and so there is an ap-
parent reduction in the associated risk with cardiovascu-
lar disease by the seventh year. This warrants further 
exploration in other cohorts as it may help to understand 
the pathological processes involved by examining defin-
ing characteristics of the different cohorts (survivors 
versus those who developed cardiovascular disease). 
The findings from this study may not be generalisable 
to other populations given the high prevalence of albu-
minuria and other CVD risk conditions especially diabe-
tes in this cohort relative to the general Australian popu-
lation. The magnitude of the risk estimates was also 
higher than has been commonly reported in the literature 
[2,4], although the reduction in risk for in the first few 
years relative to the overall hazard may be generalisable. 
There was also no difference in cardiovascular disease 
risk for women compared with men, a finding that has 
been reported from this cohort previously. This is 
thought to be a result of higher rates of metabolic disease 
especially diabetes in women compared with men and so 
eliminating the protective effect of being female [7].  
The findings of this study are possibly limited by un-
der-enumeration of outcome events. This could have 
occurred through the data linkage process as it was un-
dertaken manually, and it may also be that deaths were 
under-recorded in the latter years of the study given the 
time-lag involved in registering deaths and cause of 
death. These possible misclassification errors are likely 
to have been non-differential and so are likely to have 
had an effect of biasing the findings towards the null. For 
example, if an assumption is made that the sensitivity of 
the classification method was 95% and the specificity 
99% (an ideal test), then the biasing effect on the esti-
mate would be an increase in the relative risk from 9.7 
(the equivalent of the HR of 10.8) to 19.0 [13]. The se-
lection method for the first half of the cohort lead to 
fewer people being tested for ACR than the latter half of 
the cohort and so the results reflect that for a relatively 
high risk cohort. While this introduces a potential risk of 
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selection bias, there was no evidence for this on 
re-analysis of the data restricted to only those communi-
ties where ACR testing was universal (16 of the 26 
communities). There was minimal change in the effect 
estimates, although they were measured with less preci-
sion (data not presented, available on request from the 
authors).  
In summary, the findings here suggest that the risk of 
CVD with macroalbuminuria are not linear over time, 
and that the first three years after finding macroalbumin-
uria provide a window of opportunity to manage the risk 
of both incident and pre-existing cardiovascular disease 
before the risk of a CVD related event or death elevates 
substantially in subsequent years. These findings to-
gether suggest the need for increased use of ACR testing 
in the course of clinical care for adults, including those 
who are apparently at low risk of CVD.  
This might represent an opportunity to step up primary 
health care-based clinical intervention, especially aggres- 
sive management of albuminuria with a view to revers-
ing or reducing subsequent CVD and other events. Fur-
ther, clinicians identifying an elevated ACR should con-
sider a broader assessment of the patient and manage-
ment of potential cardiovascular risk. This change in prac- 
tice could be monitored in cohorts over time utilising 
new capabilities in unit level record linkage.  
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